Strategic Acquisition Integration Leverage the healthŌme acquisition to position Kailos as an integrated provider of clinical sequencing and health navigation, enabling cross selling of lab reagents, sequencing services, and data workflow solutions to enterprise clients within the healthŌme network and partner health systems.

Ophthalmology Collaboration Existing efforts with Advancing Sight Network and OcularGeneScreen indicate a foothold in ophthalmology and eye donor research. Target eye centers, ophthalmology departments, eye banks, and research consortia to commercialize gene panels for blinding diseases, with options for clinical testing and research services.

Workplace Testing Momentum Experience with workplace testing programs suggests scalable models for recurring health surveillance. Offer turnkey workplace testing, dashboards, and compliant workflows to employers, hospitals, and health systems seeking ongoing population health solutions.

Pharmacogenomics Expansion Past collaboration with health networks to build pharmacogenetic testing platforms signals demand for pharmacogenomics within large systems. Propose integrated pharmacogenetic panels, EHR decision support, and patient facing guidance to hospital systems, clinics, and research institutions.

Research and Lab Services As a CLIA certified lab supplying clinical grade reagents for next generation sequencing, Kailos can cultivate relationships with academic medical centers, biotech startups, and CROs needing scalable sequencing services and reagents, along with data analysis support.